<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03504540</url>
  </required_header>
  <id_info>
    <org_study_id>MMT_2018_1</org_study_id>
    <nct_id>NCT03504540</nct_id>
  </id_info>
  <brief_title>Comparison of Complement Factors and Genetic Polymorphisms of AMD Between Patients With Systemic Lupus Erythematosus (SLE) With and Without Retinal &quot;Pseudo-drusen-like&quot; Deposits: Case-control Study (PL-AMD)</brief_title>
  <acronym>PL-AMD</acronym>
  <official_title>Comparison of Complement Factors and Genetic Polymorphisms of AMD Between Patients With Systemic Lupus Erythematosus (SLE) With and Without Retinal &quot;Pseudo-drusen-like&quot; Deposits: Case-control Study (PLAMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondation Ophtalmologique Adolphe de Rothschild</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondation Ophtalmologique Adolphe de Rothschild</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The rationale of this research is to determine if patients with lupus and presenting retinal&#xD;
      &quot;pseudo-drusen-like&quot; deposits have genetic and complement-related similarities with AMD&#xD;
      patients.&#xD;
&#xD;
      Based on the results obtained, this study could lead to future research that could better&#xD;
      target the treatment of patients with lupus or patients with AMD (Age related Macular&#xD;
      Degeneration).&#xD;
&#xD;
      The primary objective is to check if patients with lupus, treated or not with antimalarial&#xD;
      drugs, with &quot;pseudo-drusen-like&quot; deposits have a different complement profile (functional&#xD;
      exploration of complement, complement factors, genetic complement polymorphisms involved in&#xD;
      AMD) compared to patients without &quot;pseudo-drusen-like&quot; deposits.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 5, 2018</start_date>
  <completion_date type="Actual">May 15, 2021</completion_date>
  <primary_completion_date type="Actual">May 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of AMD genetic polymorphisms between case and control patients</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Comparison of complement factors between case and control patients</measure>
    <time_frame>Baseline</time_frame>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">42</enrollment>
  <condition>Lupus Erythematosus</condition>
  <condition>Lupus Erythematosus, Systemic</condition>
  <condition>Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Case (with pseudo-drusen-like deposits)</arm_group_label>
    <description>Patients with lupus, treated or not with antimalarial drugs, with &quot;pseudo-drusen-like&quot; deposits</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control (without pseudo-drusen-like deposits)</arm_group_label>
    <description>Patients with lupus, treated or not with antimalarial drugs, without &quot;pseudo-drusen-like&quot; deposits</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood test</intervention_name>
    <description>Blood test for complement factors and genetic polymorphisms of AMD analysis</description>
    <arm_group_label>Case (with pseudo-drusen-like deposits)</arm_group_label>
    <arm_group_label>Control (without pseudo-drusen-like deposits)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with lupus, treated or not with APS, with ou without &quot;pseudo-drusen-like&quot; deposits&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Systemic lupus erythematosus&#xD;
&#xD;
          -  Case patients : with &quot;pseudo-drusen-like&quot; deposit&#xD;
&#xD;
          -  Control patients : without &quot;pseudo-drusen-like&quot; deposit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient under a measure of legal protection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martine MAUGET FAYSSE</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondation Ophtalmologique A. de Rothschild</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fondation ophtalmologique Adolphe de Rothschild</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 6, 2018</study_first_submitted>
  <study_first_submitted_qc>April 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2018</study_first_posted>
  <last_update_submitted>May 21, 2021</last_update_submitted>
  <last_update_submitted_qc>May 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lupus Erythematosus, Systemic</keyword>
  <keyword>Age Related Macular Degeneration</keyword>
  <keyword>&quot;Pseudo-drusen-like&quot; deposits</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

